Patents by Inventor Hiroaki Maeda

Hiroaki Maeda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20050281808
    Abstract: The present invention provides a peptide fragment or a series of peptide fragments having a cell death-inhibitory activity, having the amino acid sequence consisting of 103 amino acid residues at the C-terminal of selenoprotein P, or having said amino acid sequence with one or several amino acid residues therein being deleted, substituted or added, or having a partial sequence of either of the above amino acid sequences, a medicament for treatment comprising said peptide fragment or a series of peptide fragments, an antibody to said peptide fragment or a series of peptide fragments, and a method for screening a cell death-inhibitory activity using said peptide fragment or a series of peptide fragments. The preferable peptide fragment or a series of peptide fragments of the present invention has the amino acid sequences shown in SEQ ID NO: 1 and/or SEQ ID NO: 2 or has a partial sequence thereof.
    Type: Application
    Filed: July 21, 2005
    Publication date: December 22, 2005
    Inventors: Masaki Hirashima, Hiroaki Maeda, Chikateru Nozaki
  • Publication number: 20050143311
    Abstract: A peptide fragment or a series of peptide fragments containing one or more selenocysteine that has a lowered toxicity than selenocystine and that exhibits a cytotoxicity-inhibitory activity. The peptide fragment or a series of peptide fragments according to the present invention has preferably the amino acid sequence from 260th to 362nd amino acid residues from the C-terminal of selenoprotein P, or said amino acid sequence with one or several amino acid residues therein being deleted, substituted or added, or a partial sequence of either of the above amino acid sequences, or an amino acid sequence comprising as a part any of the above amino acid sequences. A screening method for a peptide fragment having the cytotoxicity-inhibitory activity is also provided.
    Type: Application
    Filed: May 10, 2002
    Publication date: June 30, 2005
    Inventors: Masaki Hirashima, Takeshi Naruse, Hiroaki Maeda, Chikateru Nozaki, Takeshi Goto, Katsuhiko Akiyama, Wataru Hattori
  • Publication number: 20050143310
    Abstract: A medicament for treating neurodegenerative diseases, comprising as an active ingredient selenoprotein P and/or a peptide fragment or a series of peptide fragments derived from the C-terminal of selenoprotein P. An excellent medicament for treating neurodegenerative diseases, especially suitable for treating neurodegenerative diseases with ataxia as a principal symptom is provided.
    Type: Application
    Filed: May 10, 2002
    Publication date: June 30, 2005
    Inventors: Masaki Hirashima, Takeshi Naruse, Hiroaki Maeda, Chikateru Nozaki, Takeshi Goto, Katsuhiko Akiyama, Hidenao Fukushima
  • Publication number: 20050037954
    Abstract: A novel medicament for treating neurodegenerative diseases, especially for ameliorating dyskinesia, comprising as an active ingredient selenoprotein P and/or a peptide fragment or a series of peptide fragments derived from said protein is provided. The novel medicament for treating neurodegenerative diseases, especially for ameliorating dyskinesia, according to the present invention is suitably applicable to diseases with decrease in motor function.
    Type: Application
    Filed: August 31, 2001
    Publication date: February 17, 2005
    Inventors: Masaki Hirashima, Takumi Sasaki, Takeshi Naruse, Hiroaki Maeda, Chikateru Nozaki
  • Publication number: 20040214275
    Abstract: This invention is intended to isolate and identify a vWF-specific cleaving protease.
    Type: Application
    Filed: October 22, 2003
    Publication date: October 28, 2004
    Inventors: Kenji Soejima, Noriko Mimura, Hiroaki Maeda, Chikateru Nozaki, Takayoshi Hamamoto, Tomohiro Nakagaki
  • Publication number: 20040197852
    Abstract: A process for preparing a peptide fragment having a cell death-inhibitory activity is provided. In order to obtain a selenoprotein P fragment having a cell death-inhibitory activity, full-length selenoprotein P was reacted with various serine proteinases and the resulting fragments were electrophoresed and assessed for a cell death-inhibitory activity. A process for preparing a selenoprotein P fragment was established by identifying an enzyme that produced bands corresponding to a molecular weight of not more than 3.5×104 in electrophoresis. A process for preparing a peptide fragment having a cell death-inhibitory activity according to the present invention may be used for amelioration, treatment and prevention of diseases caused by cell death and for more efficient production of useful living substances.
    Type: Application
    Filed: February 9, 2004
    Publication date: October 7, 2004
    Inventors: Shinataro Kamei, Takayoshi Hamamoto, Masaki Hirashima, Hiroaki Maeda, Hazuhiko Takahashi
  • Patent number: 6777540
    Abstract: Novel humanized immunoglobulins and active fragments thereof which are specifically reactive to Fas ligand are provided, and a site on Fas ligand which is important to inhibit apoptosis induced by the Fas-Fas ligand interaction against Fas-expressing cells is demonstrated. The novel humanized immunoglobulins and active fragments thereof which are specifically reactive to Fas ligand are prepared from hybridomas which produce monoclonal antibodies specifically reactive to Fas ligand, via recombinant DNA techniques. The humanized immunoglobulins can inhibit the physiological reactions between Fas ligand and Fas such as apoptosis. Further, identification of the site which is on Fas ligand and responsible for apoptosis induction allows creation of recombinant proteins or peptides which are specifically reactive to the amino acids within the site so as to inhibit apoptosis, and to find new therapeutic or diagnostic agents.
    Type: Grant
    Filed: April 15, 1999
    Date of Patent: August 17, 2004
    Inventors: Ko Okumura, Motomi Nakata, Hirofumi Higuchi, Yoshitaka Ushio, Hiroaki Maeda, Yasuyuki Eda
  • Publication number: 20040131620
    Abstract: A human polyclonal antibody having an antibacterial and/or antiviral activity with a desired titer and a wide spectrum; and human polyclonal antibody composition for preventing and treating infections which contain this antibody. The human polyclonal antibody composition for preventing or treating infections contain the human polyclonal antibody which is obtained by administering as immunogen a bacterium and/or a virus or a component of the bacterium and/or the virus to a non-human animal having a human antibody gene locus and has an antibody titer against the bacterium and/or the virus exceeding that of human pool plasma.
    Type: Application
    Filed: October 17, 2003
    Publication date: July 8, 2004
    Inventors: Hiroaki Maeda, Misako Umenashi, Chikateru Nozaki
  • Patent number: 6566097
    Abstract: A novel feline cytokine protein having the activity to enhance the cytotoxic activity of feline cytotoxic T lymphocytes, a DNA sequence coding for said protein, a recombinant DNA for expressing said protein, an expression vector comprising said recombinant DNA, a transformant which is transformed with said expression vector, a process for preparing said protein by culturing said transformant, and an antibody against said protein are provided. The novel feline cytokine protein of the present invention is a heterologous dimer comprising FLAF p35 and FLAF p40 and can be used for treating feline infectious diseases such as feline herpes virus type 1 (FHV-1) or feline calicivirus (FCV).
    Type: Grant
    Filed: February 22, 2002
    Date of Patent: May 20, 2003
    Assignee: Juridical Foundation The Chemo-Sero-Therapeutic Research Institute
    Inventors: Takayuki Imamura, Hiroaki Maeda, Takeshi Fujiyasu, Yoshitaka Imagawa, Sachio Tokiyoshi
  • Publication number: 20030079341
    Abstract: A first printed circuit board includes a first insulating board substantially made of thermoplastic resin and a first conductive pattern. A second printed circuit board includes a second insulating board and a second conductive pattern. The first and second printed circuit boards are overlapped. The overlapped portion of the first and second printed circuit boards is heat pressed to connect the first and second printed circuit boards with a heat-pressing tool while the first insulating board is cooled at an area adjacent to an area pressed by the heat-pressing tool. With the heat pressing, the first and second lands are electrically connected and the thermoplastic resin is softened and plastically deformed to bond the first insulating board to the second insulating board. The thickness of the first insulating board is preferably controlled at the heat pressed area and the area adjacent to the heat pressed area by the cooling.
    Type: Application
    Filed: October 31, 2002
    Publication date: May 1, 2003
    Inventors: Toshihiro Miyake, Kazuyuki Deguchi, Yoshitaro Yazaki, Hiroaki Maeda, Mitsutoshi Miyazaki, Makoto Totani, Akinari Higashida, Hiroki Miyagawa
  • Patent number: 6518045
    Abstract: A novel feline cytokine protein having the activity to enhance the cytotoxic activity of feline cytotoxic T lymphocytes, a DNA sequence coding for said protein, a recombinant DNA for expressing said protein, an expression vector comprising said recombinant DNA, a transformant which is transformed with said expression vector, a process for preparing said protein by culturing said transformant, and an antibody against said protein are provided. The novel feline cytokine protein of the present invention is a heterologous dimer comprising FLAF p35 and FLAF p40 and can be used for treating feline infectious diseases such as feline herpes virus type 1 (FHV-1) or feline calicivirus (FCV).
    Type: Grant
    Filed: April 30, 1999
    Date of Patent: February 11, 2003
    Assignee: Juridical Foundation The Chemo-Sero-Therapeutic Research Institute
    Inventors: Takayuki Imamura, Hiroaki Maeda, Takeshi Fujiyasu, Yoshitaka Imagawa, Sachio Tokiyoshi
  • Patent number: 6472509
    Abstract: A novel feline cytokine protein having the activity to enhance the cytotoxic activity of feline cytotoxic T lymphocytes, a DNA sequence coding for said protein, a recombinant DNA for expressing said protein, an expression vector comprising said recombinant DNA, a transformant which is transformed with said expression vector, a process for preparing said protein by culturing said transformant, and an antibody against said protein are provided. The novel feline cytokine protein of the present invention is a heterologous dimer comprising FLAF p35 and FLAF p40 and can be used for treating feline infectious diseases such as feline herpes virus type 1 (FHV-1) or feline calicivirus (FCV).
    Type: Grant
    Filed: February 4, 1998
    Date of Patent: October 29, 2002
    Assignee: Juridical Foundation: The Chemo-Seso-Therapeutic Research Institute
    Inventors: Takayuki Imamura, Hiroaki Maeda, Takeshi Fujiyasu, Yoshitaka Imagawa, Sachio Tokiyoshi
  • Publication number: 20020107366
    Abstract: A novel feline cytokine protein having the activity to enhance the cytotoxic activity of feline cytotoxic T lymphocytes, a DNA sequence coding for said protein, a recombinant DNA for expressing said protein, an expression vector comprising said recombinant DNA, a transformant which is transformed with said expression vector, a process for preparing said protein by culturing said transformant, and an antibody against said protein are provided. The novel feline cytokine protein of the present invention is a heterologous dimer comprising FLAF p35 and FLAF p40 and can be used for treating feline infectious diseases such as feline herpes virus type 1 (FHV-1) or feline calicivirus (FCV).
    Type: Application
    Filed: February 22, 2002
    Publication date: August 8, 2002
    Applicant: Takara Shuzo Co., Ltd.
    Inventors: Takayuki Imamura, Hiroaki Maeda, Takeshi Fujiyasu, Yoshitaka Imagawa, Sachio Tokiyoshi
  • Patent number: 6342124
    Abstract: An aqueous alkaline slurry of cellulose pulp is bleached with oxygen or peroxide by using a compound represented by general formula (1), (2) or (3) as a bleaching assistant: R1—O—[(C2H4O)m/(AO)n]—H  (1) R2—O—[(C2H4O)m/(AO)p]—(AO)q—H  (2) (R3)t—X—[(C2H4O)m/(AO)p]—(AO)r—H  (3) where R1 stands for a branched alkyl group having 6 to 12 carbon atoms, m stands for an average added mol number of 4 to 15, A stands for a propylene, butylene or phenylethylene group, n stands for an average added mol number of 0 to 4, the addition shown in [ ] is in a random or block form, R2 stands for a linear or branched alkyl group having 6 to 12 carbon atoms, p stands for an average added mol number of 0 to 3.9, q stands for an average added mol number of 0.
    Type: Grant
    Filed: April 13, 2001
    Date of Patent: January 29, 2002
    Assignee: Sanyo Chemical Industries, Ltd.
    Inventors: Hiroaki Maeda, Daisuke Nakamura, Nobuo Hisada
  • Publication number: 20010017196
    Abstract: An aqueous alkaline slurry of cellulose pulp is bleached with oxygen or peroxide by using a compound represented by general formula (1), (2) or (3) as a bleaching assistant:
    Type: Application
    Filed: April 13, 2001
    Publication date: August 30, 2001
    Applicant: SANYO CHEMICAL INDUSTRIES, LTD.
    Inventors: Hiroaki Maeda, Daisuke Nakamura, Nobuo Hisada
  • Patent number: 6248209
    Abstract: An aqueous alkaline slurry of cellulose pulp is bleached with oxygen or peroxide by using a compound represented by general formula (1), (2) or (3) as a bleaching assistant: R1—O—[(C2H4O)m/(AO)n]—H  (1) R2—O—[(C2H4O)m/(AO)p]—(AO)q—H  (2) (R3)t—X—[(C2H4O)m/(AO)p]—(AO)r—H  (3) where R1 stands for a branched alkyl group having 6 to 12 carbon atoms, m stands for an average added mol number of 4 to 15, A stands for a propylene, butylene or phenylethylene group, n stands for an average added mol number of 0 to 4, the addition shown in [ ] is in a random or block form, R2 stands for a linear or branched alkyl group having 6 to 12 carbon atoms, p stands for an average added mol number of 0 to 3.9, q stands for an average added mol number of 0.
    Type: Grant
    Filed: October 28, 1997
    Date of Patent: June 19, 2001
    Assignee: Sanyo Chemical Industries, Ltd.
    Inventors: Hiroaki Maeda, Daisuke Nakamura, Nobuo Hisada
  • Patent number: 6161672
    Abstract: A shift-locking device for a vehicle transmission includes a manual shaft mechanically connected with a shift lever for rotating to a first position, a second position and a third position through operation of the shift lever, and mechanically connected to a parking control mechanism disposed in the transmission case. A first shift-locking shaft is connected to a brake pedal for rotating from a first position to a second position, and a locked member is provided on the manual shaft. A first lock member provided on the first shift-locking shaft is adapted to engage the locked member when the first shift-locking shaft is in the first position. A spring urges the first shift-locking shaft to the second position to release engagement between the locked member and the first lock member.
    Type: Grant
    Filed: September 24, 1999
    Date of Patent: December 19, 2000
    Assignee: Aisin Seiki Kabushiki Kaisha
    Inventors: Hiroaki Maeda, Yuki Tojima, Shigeki Banno
  • Patent number: 6114143
    Abstract: A monoclonal antibody useful for clinical application which recognizes the conserved region of V3-PND region of glycoprotein antigen having a molecular weight of about 1.2.times.10.sup.5 daltons (gp120) on a coating membrane of human immunodeficiency virus (HIV) and which has an ability to neutralize a broad range of various HIV variants, or a fragment thereof, and the chimeric and humanized antibodies derived therefrom are provided. By using as an immunogen a plurality of peptides having PND-Tip region containing the highly conserved GPGR sequence within PND of HIV gp120, a monoclonal antibody having a neutralizing activity to many HIV variants can be prepared. By transplanting the gene fragment coding for the variable region of said monoclonal antibody or complementarity determining region (CDR) of said region to a human antibody gene, a chimeric antibody or a reshaped antibody having an anti-HIV neutralizing activity which are effective for clinical application can be obtained.
    Type: Grant
    Filed: September 11, 1995
    Date of Patent: September 5, 2000
    Assignee: Juridical Foundation The Chemo-Sero-Therapeutic Research Institute
    Inventors: Yasuyuki Eda, Hiroaki Maeda, Keiichi Makizumi, Kouichi Shiosaki, Kiyoshi Osatomi, Kazuhiko Kimachi, Hirofumi Higuchi, Sachio Tokiyoshi
  • Patent number: 6074321
    Abstract: A transaxle assembly comprising, a planetary gear unit including a planetary gear set to shift receiving torque from a power source, a differential including a differential case, a cross pin having a pinion gear and a pair of output members, each output member having a differential side gear to engage with the pinion gear respectively, the differential transmitting the torque from the planetary gear unit to the output members via a circled carrier connecting between the planetary gear unit and the differential, wherein the planetary gears located outside of the differential case, the carrier supporting both ends of the cross pin and contacting with the differential case.
    Type: Grant
    Filed: September 30, 1998
    Date of Patent: June 13, 2000
    Assignee: Aisin Seiki Kabushiki Kaisha
    Inventors: Hiroaki Maeda, Yuki Tojima
  • Patent number: 5880274
    Abstract: A Gene fragment which comprises a DNA sequence coding for an amino acid sequence of a constant region of feline immunoglobulin .lambda. chain; a gene fragment which comprises a DNA sequence coding for an amino acid sequence of a constant region of feline immunoglobulin .kappa. chain; a gene fragment which comprises a DNA sequence coding for the constant region of feline immunoglobulin .gamma.
    Type: Grant
    Filed: November 17, 1995
    Date of Patent: March 9, 1999
    Assignee: Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute
    Inventors: Hiroaki Maeda, Yasuyuki Eda, Kazuhiko Kimachi, Yoichi Ono, Sachio Tokiyoshi